Grants

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

National Institutes of Health

The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope of the program includes lead optimization, early-stage development activities, IND-enabling studies, development of pharmacodynamic and/or target engagement biomarkers, preparation and submission of an Investigational New Drug (IND) application, and Phase I clinical testing. This is a milestone-driven, phased cooperative agreement program that involves active participation by NIH program staff in project planning and ongoing monitoring of research progress.

2029-02-20

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

National Institutes of Health

2029-02-20

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Optimization of Therapeutic Medical Devices through Team Science Mechanistic Research (RM1)

National Institutes of Health

The National Institute of Neurological Disorders and Stroke (NINDS), with other NIH Institutes and Centers (ICs), intends to publish a Notice of Funding Opportunity (NOFO) to investigate the mechanisms of action of therapeutic medical devices with the overall goal of improving clinical outcomes with device-based approaches. Medical devices are essential in managing health conditions, complementing drugs and behavioral interventions, and often offer unique benefits. Despite the commercial availability of numerous medical devices and ongoing development of new technologies, many have shown inconsistent results in preclinical studies, failed translation to humans, and exhibit varied patient outcomes. To overcome these challenges, it is crucial to understand the mechanisms by which medical devices produce a therapeutic effect, to identify physiological markers of neurological conditions, and to assess how device-based therapies influence these markers. Advancing this knowledge will improve device-based interventions, inspire new device designs, and optimize current clinical approaches.Applications will be invited from interdisciplinary teams pursuing innovative research on how medical devices produce a therapeutic effect. Applicant teams will likely exhibit expertise in areas such as engineering, biology, pathophysiology, surgery, clinical care, healthcare delivery, biostatistics, software development, computational modeling, artificial intelligence, regulatory science, and clinical trials. This program will accept projects on investigational devices and those already FDA-approved and in clinical use. Applications are expected to include strategies for developing or optimizing therapies that could significantly improve patient care. Supported research may include mechanistic clinical trials, animal studies, and computational modeling or simulation. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

2026-10-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Optimization of Therapeutic Medical Devices through Team Science Mechanistic Research (RM1)

National Institutes of Health

The National Institute of Neurological Disorders and Stroke (NINDS), with other NIH Institutes and Centers (ICs), intends to publish a Notice of Funding Opportunity (NOFO) to investigate the mechanisms of action of therapeutic medical devices with the overall goal of improving clinical outcomes with device-based approaches. Medical devices are essential in managing health conditions, complementing drugs and behavioral interventions, and often offer unique benefits. Despite the commercial availability of numerous medical devices and ongoing development of new technologies, many have shown inconsistent results in preclinical studies, failed translation to humans, and exhibit varied patient outcomes. To overcome these challenges, it is crucial to understand the mechanisms by which medical devices produce a therapeutic effect, to identify physiological markers of neurological conditions, and to assess how device-based therapies influence these markers. Advancing this knowledge will improve device-based interventions, inspire new device designs, and optimize current clinical approaches.Applications will be invited from interdisciplinary teams pursuing innovative research on how medical devices produce a therapeutic effect. Applicant teams will likely exhibit expertise in areas such as engineering, biology, pathophysiology, surgery, clinical care, healthcare delivery, biostatistics, software development, computational modeling, artificial intelligence, regulatory science, and clinical trials. This program will accept projects on investigational devices and those already FDA-approved and in clinical use. Applications are expected to include strategies for developing or optimizing therapies that could significantly improve patient care. Supported research may include mechanistic clinical trials, animal studies, and computational modeling or simulation. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

2026-10-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

National Institutes of Health

HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

research

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)

National Institutes of Health

The purpose of this initiative is to: (1) support the efforts by R15-eligible Principal Investigators (PIs) to conduct rigorous basic and/or mechanistic pain research projects; (2) promote integrated, interdisciplinary research partnerships between R15-eligible PIs and additional investigators from U.S. domestic institutions, and (3) enhance the pain research environment at the R15-eligible institution for health professional trainees or undergraduate and/or graduate students by actively engaging them in the proposed pain research projects.

Up to $375K

2026-11-23

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins and the Nature of (PRECISION) Human Pain Network

National Institutes of Health

The National Institute of Neurological Disorders and Stroke, in conjunction with other NIH Institutes and Centers (ICs) as a part of the congressionally mandated <a href="https://heal.nih.gov/">NIH Helping to End Addiction Long Term (HEAL) initiative</a> intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for  comprehensive ‘omics and physiology dataset generation using primary human tissue across the pain neuraxis. Applications should focus on large-scale, high-throughput data generation and analysis of human genes, epigenome, transcriptome, proteome, metabolome, and phenotyping of neuronal and non-neuronal cells at the single-cell and tissue levels. This NOFO is intended as a continuation of the NIH HEAL Initiative’s <a href="https://sparc.science/about/consortia/precision">Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins and the Nature of (PRECISION) Human Pain Network</a>. The goal of this research will be to expand the generation and dissemination of comprehensive datasets using primary pain-associated human tissues, incorporate cutting-edge technologies, enhance coverage across multiple pain conditions, and extend integration and harmonization of multimodal outputs. This NOFO will utilize a milestone-driven, cooperative agreement mechanism, in which awarded centers will work collaboratively as a network to develop best practices, optimize protocols, replicate and cross-validate research findings, and collectively build an integrated knowledgebase, with digital resources for the entire pain research and therapeutics development communities. NIH program staff involvement is expected to coordinate alignment with the broader <a href="https://heal.nih.gov/data/heal-data-ecosystem">HEAL Data Sharing Ecosystem</a> and account for evolving priorities to ensure program objectives are achieved.Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful multidisciplinary collaborations and responsive projects. Investigators with expertise and insights into comprehensive ‘omics and physiology dataset generation in primary human tissue are encouraged to consider applying for this NOFO. In addition, applications from collaborating, multidisciplinary teams of neurobiologists, pain biologists, human pain scientists and/or physicians, surgeons, and scientists with expertise in statistics, physics, engineering, and bioinformatics should consider applying to this funding opportunity.

2026-10-12

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins and the Nature of (PRECISION) Human Pain Network

National Institutes of Health

The National Institute of Neurological Disorders and Stroke, in conjunction with other NIH Institutes and Centers (ICs) as a part of the congressionally mandated NIH Helping to End Addiction Long Term (HEAL) initiative intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for comprehensive omics and physiology dataset generation using primary human tissue across the pain neuraxis. Applications should focus on large-scale, high-throughput data generation and analysis of human genes, epigenome, transcriptome, proteome, metabolome, and phenotyping of neuronal and non-neuronal cells at the single-cell and tissue levels. This NOFO is intended as a continuation of the NIH HEAL Initiative s Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins and the Nature of (PRECISION) Human Pain Network. The goal of this research will be to expand the generation and dissemination of comprehensive datasets using primary pain-associated human tissues, incorporate cutting-edge technologies, enhance coverage across multiple pain conditions, and extend integration and harmonization of multimodal outputs. This NOFO will utilize a milestone-driven, cooperative agreement mechanism, in which awarded centers will work collaboratively as a network to develop best practices, optimize protocols, replicate and cross-validate research findings, and collectively build an integrated knowledgebase, with digital resources for the entire pain research and therapeutics development communities. NIH program staff involvement is expected to coordinate alignment with the broader HEAL Data Sharing Ecosystem and account for evolving priorities to ensure program objectives are achieved.Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful multidisciplinary collaborations and responsive projects. Investigators with expertise and insights into comprehensive omics and physiology dataset generation in primary human tissue are encouraged to consider applying for this NOFO. In addition, applications from collaborating, multidisciplinary teams of neurobiologists, pain biologists, human pain scientists and/or physicians, surgeons, and scientists with expertise in statistics, physics, engineering, and bioinformatics should consider applying to this funding opportunity.

2026-10-12

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)

National Institutes of Health

This funding opportunity is part of a suite of NOFOs within the NIH HEAL Initiative to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal is to encourage initial translational efforts that will support a drug discovery program and advance projects to the point where they meet the entry criteria for the Pain Therapeutics Development Program. The scope will therefore be focused on development of assays to support a distinct testing funnel, screening efforts to identify hits, and initial characterization of hits and potential therapeutic agents (including small molecules, biologics, and natural products).

Up to $350K

2027-01-15

Education

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)

National Institutes of Health

The goal of this notice of funding opportunity (NOFO) is to address the opioid crisis and/or overdose events by supporting action-oriented research, accelerating the translation of addiction epidemiology, prevention, treatment services, and recovery research to practice. Proposed studies may target the individual, provider, organizational, community, or system level. This initiative prioritizes replicable and scalable approaches for accelerating the routine use of effective, evidence-based prevention, treatment and recovery interventions and services. The translation of research to practice and research relevant to chronic pain comorbid with substance use is also a priority. Research may deploy a variety of methods and approaches, including but not limited to identifying and characterizing malleable factors, developing and testing interventions and implementation strategies, deploying and testing collaborative data science approaches, and/or developing and testing approaches that integrate the collaboration of researchers and decision-makers at any levels (e.g., clinical-, health system-, public health- or policy-level).

2029-02-09

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)

National Institutes of Health

2029-02-09

Free to search & build · $99 one-time to unlock the application pack · No subscription

HEALTH & GROUP BENEFITS CONSULTING

DELOITTE CONSULTING LLP

Financial and Insurance Services

2027-07-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Canada — Mental Health and Substance Use

Health Canada

Grants for community-based mental health promotion, substance use prevention, and harm reduction programs across Canada.

$25K – $2M

mental-healthsubstance-useharm-reduction

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Center Program Performance Period Extensions; Correction

Health and Human Services Department

HRSA is extending health center grantees' performance periods to a total of 4 years. The change from a 3-year performance period to a 4-year performance period will provide current health centers additional time to serve their service area before they apply for a new award and will provide a funding amount consistent with what would have been made available through the Service Area Competition (SAC). The extended performance period supports HRSA's commitment to continuity in access to comprehensive primary care and will not impact HRSA's ability to ensure that health centers comply with Health Center Program requirements. This update will not change the statutory requirement that health centers that fail to comply with Health Center Program requirements will receive a 1-year performance period if a new project period is awarded.

See notice

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Check-Up for Expectant Moms: Technology-Based Intervention for Improving Well Being of Rural Pregnant Women

NIDA - National Institute on Drug Abuse

PROJECT SUMMARY Alcohol, tobacco, and other drug use (ATOD), sexual health risks, and postpartum depression (PPD) are common and significant interrelated factors that are associated with poor health consequences for pregnant women and their infants, especially among rural, under-resourced communities. Thus, there is an urgent need to simultaneously address these health risks together during this vulnerable time. While pregnancy has been recognized as a window of opportunity in which to intervene, there are no empirically supported interventions tailored to specifically address these growing public health concerns together in rural women during pregnancy and postpartum. The objective of this R01 study is to fill this critical gap by building upon our promising R21/R01 findings by (1) partnering with a community advisory board to adapt and optimize the existing Health Check-up for Expectant Moms (HCEM) web-delivered Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) program to include the interconnected risks of tobacco use and postpartum depression (PPD) among rural pregnant women (herein referred to as HCEM+), and (2) testing the efficacy of the HCEM+ in reducing ADOT, STI, and PPD risk more than a time and information matched control condition in rural pregnant women seeking prenatal care. This research addresses cross-cutting priorities in line with NIDA’s Strategic Plan to advance science on drug use: (1) prioritizing research to combat stigma and improve engagement in treatment, (2) developing and enhancing culturally responsive and tailored interventions, and (3) delivering care for substance use and co-occurring health conditions such as STIs and mental illness. We propose a two-group, randomized controlled trial in which a sample of 250 high-risk rural pregnant women attending prenatal care will be assigned to either (a) a web-delivered, two-session SBIRT/P plus two booster sessions consistent with motivational interviewing and informed by the Information-Motivation-Behavior (IMB) model, the HCEM+, or (b) a web-delivered control condition. Web-delivered follow-up assessments will occur at 8 and 24 weeks antenatally, and at 6 weeks postpartum, extending outcomes to the postpartum period. Specific Aim 1 is to test the hypothesis that HCEM+, compared to an attention, time and information matched control condition, will reduce unprotected sexual occasions and ADOT use among at-risk pregnant women during pregnancy at 2 and 6-months follow-up, and will increase treatment engagement. Specific Aim 2 is to test the hypothesis that HCEM+, compared to control, will reduce STIs and ADOT use at 6 weeks postpartum and will result in better birth outcomes and reduced rates of PPD. An economic evaluation of the costs of the HCEM+ will occur to guide future implementation and dissemination. Results of this program of research are expected to inform the development of a practical, cost-effective, high-reaching web-delivered SBIRT/P program tailored to reach high-risk rural and under-resourced women with extended impact to the postpartum period.

Up to $570K

2031-02-28

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Equity Data Access Program (HEDAP)

Center for Medicare and Medicaid Services

Health Equity Data Access Program (HEDAP)

equityHealth

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Equity Data Access Program (HEDAP)

Center for Medicare and Medicaid Services

The Health Equity Data Access program (HEDAP) provides funding for six (6) “seats” in the <a href="https://www.resdac.org/cms-virtual-research-data-center-vrdc" target="_blank">CMS Virtual Research Data Center (VRDC).</a> The VRDC assists researchers in gaining access to CMS restricted data for minority health research. Seats, in this context are defined as an individual user with VRDC access. These researchers will conduct health services research on health care topics such as physical health, oral health, behavioral health, population health, and social determinants of health focusing on, but not limited to, racial and ethnic minority groups; people with disabilities; members of the lesbian, gay, bisexual, transgender, and queer (LGBTQ+) community; individuals with limited English proficiency; individuals residing in rural areas; and individuals (including children, youth, and families) adversely affected by persistent poverty or inequality. The HEDAP supports specific applied research projects that relate to creative and innovative methods utilizing CMS data to identify, document, assess, and evaluate health disparities among Medicare and Medicaid and CHIP enrollees.    The project should enhance the capacity of the researcher to understand and utilize CMS data in future research projects. Additionally, HEDAP encourages cutting-edge proposals that explore intersectionality. “Intersectionality” <a href="https://www.cdc.gov/healthcommunication/HealthEquityGuidingPrinciples.pdf" target="_blank">means that people belong to more than one group and, therefore, may have overlapping health and social inequities, as well as overlapping strengths and assets</a>.    Results of the HEDAP will provide CMS and its partners, (e.g. Quality Improvement Organizations, Hospital Engagement Networks, and other stakeholders) with actionable information on the subgroups of enrollees. This will aid the efforts of CMS and its agents to identify and eradicate health disparities in underserved populations.    VRDC seat access will be funded for a period of 36 months each, based on the availability of funds.

Up to $90K

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed

Food and Drug Administration

The purpose of this notice of funding opportunity (NOFO) is to fund innovative research that will strengthen and advance minority health and health equity objectives. Areas of interest include: Proposals that focus on advancing equity in clinical trials by supporting efforts to advance diversity in clinical trials, equitable data efforts by increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography, and equity of voices by increasing understanding of diverse patient perspectives, preferences, and unmet needs.

$1M

consumer_protectionAgriculturefood_and_nutrition

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed

Food and Drug Administration

Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed

innovationequityHealth

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Forward Foundation — KC Health Grants

Health Forward Foundation

Funds health equity and community health programs in the Kansas City region.

$10K – $300K

health equitycommunity healthKansas City

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Foundation for Western & Central NY — Regional Health

Health Foundation for Western & Central NY

Funds health improvement programs in western and central New York.

$10K – $250K

community healthhealth accessNew York

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Promotion Among Racial and Ethnic Minority Males (R01)

National Institutes of Health

-Purpose. This Funding Opportunity Announcement (FOA) solicits Research Project (R01) grant applications from applicants that propose to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: 1) enhance our understanding of the numerous factors (e.g., sociodemographic, community, societal, personal) influencing the health promoting behaviors of racial and ethnic minority males and their subpopulations across the life cycle, and 2) solicit applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their subpopulations age 21 and older. -Mechanism of Support. This FOA will use the Research Project (R01) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-07-421 that solicits applications under the R21 mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

rolling

Education

Free to search & build · $99 one-time to unlock the application pack · No subscription

Health Promotion Among Racial and Ethnic Minority Males (R21)